Wallaby Medical has partnered with Japan Lifeline (JLL) to bring its Pharmaceuticals and Medical Devices Agency (PMDA)-approved Avenir coil system to the Japanese market. Avenir is used in the intravascular embolisation of intracranial aneurysms and other neurovascular malformations, such as arteriovenous malformations (AVMs) and arteriovenous fistulas (AVFs), as well as arterial and venous embolisation of peripheral blood vessels.
Stroke accounts for more than 125,000 deaths annually in Japan and is one of the leading causes of death, according to a press release from Wallaby. The company’s vision is to become the medical technology company that saves the greatest number of lives of people affected by stroke—and thus Japan is one of the most important markets to serve, it adds.
The release further states that the Avenir coil system is designed with three outstanding features: exceptional complex framing, ultra-soft finishing, and an innovative, highly reliable instant detachment system.
Its proprietary design includes a reduced first loop diameter of coils to minimise coil herniation during aneurysm introduction. The exceptional framing effect provides excellent wall apposition and implant distribution to facilitate dense packing. In addition, the device’s ultra-soft finishing coils and ultra-fine primary wire enhance softness and conformability, allowing for optimal space seeking capability for the deployed coils to realise higher packing density, the release claims.
“We are dedicated to improving stroke patient care and this partnership enables us to cover the entire Japan market immediately,” said Michael Alper, Wallaby Medical CEO. “JLL’s exceptional reach and relationships mean Japanese physicians will now have the Avenir coil system as the go-to device to deliver the best possible outcome for their patients.”
